ArticleCase reports in dermatology
Baboon Syndrome Triggered by Diclofenac Potassium: A Case Report of Symmetrical Drug-Related Intertriginous and Flexural Exanthema.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Baboon syndrome, also known as symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), is a rare reaction characterised by distinct, bilateral erythema in the flexural and intertriginous regions, occurring without systemic symptoms. Case Presentation: We present a 53-year-old gentleman who, 3 days after commencing diclofenac potassium for knee pain, exhibited symmetrical, well-defined erythema affecting the neck, axillae, cubital and popliteal fossae, forearms, inguinal folds, thighs, legs, and feet. He displayed no systemic symptoms or fever. The time and distinctive distribution of SDRIFE induced by diclofenac potassium were congruent. Management and Outcome: Following the cessation of diclofenac potassium, the patient received topical corticosteroids and oral antihistamines. The symptoms resolved after 1 week. Conclusion: This case highlights the necessity for physicians to identify this presentation for prompt diagnosis and care and also indicates diclofenac potassium as a possible cause of SDRIFE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.